920-106 braindumps | Real exam Questions | Practice Tests - coqo.com

Get our up to date and valid 920-106 dumps with real exam questions and practice tests that you just memorize and take the test and pass with high marks - coqo.com

Pass4sure 920-106 dumps | Killexams.com 920-106 existent questions | http://coqo.com/

920-106 NNCSS SYMPOSIUM convoke CENTER

Study pilot Prepared by Killexams.com Nortel Dumps Experts


Killexams.com 920-106 Dumps and existent Questions

100% existent Questions - Exam Pass Guarantee with lofty Marks - Just Memorize the Answers



920-106 exam Dumps Source : NNCSS SYMPOSIUM convoke CENTER

Test Code : 920-106
Test title : NNCSS SYMPOSIUM convoke CENTER
Vendor title : Nortel
: 90 existent Questions

Nice to hear that actual test questions of 920-106 exam are available.
I acquire earned higher scores in 920-106 certification with the attend of quite inexpensive products. I got 920-106 exam engine to find rid of difficult standards of this certification. I had sold 920-106 exam braindump to acquire splendid grades within the certification. It cessation up pinnacle selection due to the fact the ones merchandise are designed in line with my brain-set. It helped me to find read in fifteen days and after this brief time I had scored specific with the attend of these practical merchandise consequently im writing to mention manner to totality of you in your top class services.


it's miles unbelieveable, but 920-106 present day dumps are availabe perquisite here.
Today I am very ecstatic because I acquire got a very lofty score in my 920-106 exam. I couldnt think I would live able to Do it but this killexams.com made me think otherwise. The online educators are doing their job very well and I salute them for their dedication and devotion.


No fritter of time on searhching internet! institute exact source of 920-106 .
I moreover had a splendid revel in with this training set, which led me to passing the 920-106 exam with over ninety eight%. The questions are existent and valid, and the exam simulator is a tremendous/guidance device, despite the fact that you are no longer planning on taking the exam and sincerely want to expand your horizons and enlarge your knowledge. i acquire given mine to a pal, who furthermore works on this position but clearly received her CCNA. What I imply is its a splendid reading device for absolutely everyone. And if you map to purchase the 920-106 exam, this is a stairway to achievement :)


Take whole gain state-of-the-art 920-106 actual examination and find licensed.
Going thru killexams.com has arrive to live a addiction whilst exam 920-106 comes. And with test springing up in pretty a whole lot 6 days changed into getting extra critical. But with subjects I want a few reference manual to sprint occasionally in order that i would find better help. Manner to killexams.com their that made it totality simple to find the subjectsinterior your head easily which would in any other case might live no longer viable. And its far totality because of killexams.com products that I controlled to gain 980 in my exam. Thats the highest marks in my beauty.


simply try those modern-day dumps and achievement is yours.
Knowing thoroughly about my time constraint, commenced out trying to find an antiseptic way out before the 920-106 exam. After a protracted searh, placed the question and answers via way of killexams.com which without a doubt made my day. Offering totality probably questions with their quick and pointed solutions helped hold near subjects in a brief time and felt ecstatic to secure existent marks inside the exam. The materials furthermore are antiseptic to memorise. I am inspired and satiated with my results.


much less effort, fanciful expertise, assured success.
I was 2 weeks short of my 920-106 exam and my preparation was not totality done as my 920-106 books got burnt in fire incident at my place. totality I thought at that time was to quit the option of giving the paper as I didnt acquire any resource to prepare from. Then I opted for killexams.com and I silent am in a condition of shock that I cleared my 920-106 exam. With the free demo of killexams.com, I was able to grasp things easily.


Did you attempted this outstanding supply cutting-edge 920-106 dumps.
killexams.com works! I passed this exam last drop and at that time over 90% of the questions were absolutely valid. They are highly likely to silent live valid as killexams.com cares to update their materials frequently. killexams.com is a mighty organization which has helped me more than once. I am a regular, so hoping for discount for my next bundle!


Is there 920-106 exam modern sayllabus?
I just bought this 920-106 braindump, as soon as I heard that killexams.com has the updates. Its genuine, they acquire covered totality modern areas, and the exam appears very fresh. Given the current update, their circle round time and attend is top notch.


actual 920-106 questions and accurate solutions! It warrant the charge.
because of 920-106 certificates you purchased many possibilities for security specialists development on your career. I wanted to development my vocation in information protection and desired to grow to live certified as a 920-106. if so I decided to purchase attend from killexams.com and commenced my 920-106 exam training through 920-106 exam cram. 920-106 exam cram made 920-106 certificates research smooth to me and helped me to obtain my desires effortlessly. Now im able to whisper without hesitation, without this internet site I in no way passed my 920-106 exam in first strive.


How much does it cost 920-106 qustions bank with existent dumps
Yes, the questions and answers could live very useful and i hint it to totality people who wants to purchase those checks. Congrats on a process nicely view out and completed. I cleared my 920-106 tests.


Nortel NNCSS SYMPOSIUM convoke CENTER

VoIP certification tracks - Nortel's uphold certifications | killexams.com existent Questions and Pass4sure dumps

As outlined in a outdated tip, companies are implementing IP telephony more commonly on their facts infrastructures. The accelerated deployment has created a exigency for certified IP telephony engineers to deliver proven, most beneficial-of-breed expertise.

The IP telephony certifications Nortel at present presents are divided into four classes: pilot specialist, Design expert, uphold skilled, and Design skilled. This tip discusses the Nortel uphold music.

assist specialist

The pilot professional certifications are intended to demonstrate an individual's means to Put into effect, operate, and troubleshoot a Nortel Networks IP Telephony answer. The uphold expert certification reflects a candidate with three to six months of event that can deal with pursuits technical issues of a common Nortel IP Telephony answer.

NNCSS - VoIP Succession BCM 3.0

This certification checks the skill to Put into effect, function, and troubleshoot the company Communications supervisor three.0. This certification covers hardware, beginning-up, facts and voice networking, applications, and troubleshooting the BCM. To flow the certification, two checks exigency to live successfully completed: know-how requisites and Protocols for IP Telephony options, and Succession BCM three.0. The technology necessities and Protocols for IP Telephony solutions exam is an contour of convergence technologies.

NNCSS - CallPilot Rls. 2.0

This certification exams the means to Put in force, function, and troubleshoot the VoIP CallPilot 2.0. This certification covers hardware, administration, interoperability with Meridian 1 switches, and security of a single website CallPilot system. To flow the certification, two tests must live successfully achieved: Meridian Database and CallPilot 2.0.

NNCSS - Symposium title middle Server or Symposium title center Server installation and protection

These two certifications stare at various the skill to implement, operate, and troubleshoot the Symposium title center Server. both certifications cover hardware, utility installing, administration, and protection of Symposium convoke core Server 4.2, Symposium web client 4.0, and Symposium categorical three.0. besides the fact that children, the Symposium convoke center Server certification furthermore tests the architecture, customized configuration and integration of the server. To pass either of those certifications, one exam acquire to live efficiently achieved: Symposium convoke center or Symposium convoke core installation and maintenance, respectively.

NNCSS - Symposium convoke center TAPI/Agent or convoke center TAPI/Agent installing and preservation

These two certifications verify the capacity to Put in force, operate, and troubleshoot the Symposium title center TAPI/Agent. each certifications cover hardware, software setting up, administration, and renovation of Symposium TAPI 2.three and Symposium Agent 2.three. however, the Symposium convoke center TAPI/Agent certification furthermore checks the structure, integration, and custom configuration of the TAPI/Agent. To sprint both of those certifications, one examination must live efficaciously completed: Symposium convoke middle TAPI/Agent or Symposium convoke core TAPI/Agent Inst/leading, respectively.

NNCSS - Symposium specific convoke core or Symposium express title middle installation and renovation

These certifications examine the capacity to enforce, function, and troubleshoot the Symposium specific title middle. both certifications cowl hardware, utility installing, administration, and protection of Symposium express convoke center four.2. despite the fact, the Symposium categorical convoke center certification furthermore checks the structure and integration of the title middle. To flow both of the certifications, one examination ought to live efficiently accomplished: Symposium categorical convoke center or Symposium categorical convoke center Inst and Maint respectively.

NNCSS - VoIP Multimedia communique Server (MCS) 5100 2.0

This certification tests the capability to implement, operate, and troubleshoot the VoIP Multimedia verbal exchange Server (MCS) 5100 2.0. This certification covers setting up of the hardware and application, configuration, preservation, and administration of the Multimedia communication Server (MCS) 5100 2.0. To sprint the certification, two assessments must live efficiently achieved: expertise standards and Protocols for IP Telephony solutions, and VoIP Multimedia verbal exchange Server (MCS) 5100 2.0. The know-how specifications and Protocols for IP Telephony options examination is an overview of convergence technologies.

NNCSS - VoIP Succession 1000/1000M Rls. 3.0 DB Administrator

This certification checks the potential to preserve and troubleshoot the VoIP Succession 1000/1000M Rls. three.0 DB Administrator. This certification covers the structure, configuration, upkeep, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. 3.0 the employ of simple Alternate Route alternative (BARS) and network Alternate Route selection (NARS). To circulate the certification, two tests exigency to live successfully completed: expertise requisites and Protocols for IP Telephony solutions, and Succession a thousand/1000M Rls. 3.0 DB Administrator.

NNCSS - VoIP Succession one thousand/1000M Rls. three.0 setting up and upkeep

This certification exams the capacity to set up, configure, and maintain the VoIP Succession 1000/1000M Rls. 3.0. This certification covers the setting up, structure, configuration, preservation, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. three.0, cyber web Telephones i2xxx, and Optivity Telephony manager (OTM) 2.1. To circulate the certification, three tests must live efficaciously achieved: know-how specifications and Protocols for IP Telephony solutions, and Succession 1000/1000M Rls. 3.0 for Technicians, and Succession 1000/1000M Rls. three.0.

support professional

The aid expert certifications build on the specialist's expertise by demonstrating their capacity to Put in force, operate, and troubleshoot an advanced Nortel Networks IP Telephony solution. The attend professional certifications reflect a candidate with six to twelve months of fingers-on journey with the means to lead or aid intermediate-level personnel to preserve complicated Nortel IP Telephony solutions.

NNCSE - CallPilot 2.0 Unified Messaging options

This certification assessments the capacity to enforce, operate, troubleshoot and optimize the VoIP CallPilot Unified Messaging solution 2.0. This certification covers the installing, administration, interoperability, security, better techniques and feature usage for a multi web site CallPilot system. To pass the certification, the candidate exigency to first gain their NNCSS - CallPilot Rls. 2.0. consequently, the CallPilot 2.0 Unified Messaging solutions acquire to live efficaciously completed to acquire this certification.

NNCSE - Contact middle

This certification checks the potential to Put into effect, operate, troubleshoot and optimize the Contact center products. This certification covers the candidate's capabilities on the Symposium convoke middle Server (SCCS)/Symposium express convoke middle/Symposium net customer, Symposium TAPI service provider (TAPI SP), Symposium Agent, and the Symposium net center Portal. To circulate the certification, the candidate ought to first acquire their NNCSS - Symposium title center Server and the NNCSS - Symposium convoke center TAPI/Agent certification. in consequence, the Contact middle examination acquire to live correctly accomplished to reap this certification.

NNCSE - IP Convergence Succession 1000/1000M Rls. 3.0

This certification checks the means to deploy, configure, retain, and optimize the VoIP Succession 1000/1000M Rls. 3.0. This certification covers the configuration, succession department office (BO), remote workplace, operation, and Meridian 1 to Succession 1000M three.0 migration procedures for the Succession a thousand/1000M Rls. 3.0, web Telephones i2xxx, faraway office 91xx, and Optivity Telephony manager (OTM) 2.1. To pass the certification, the candidate acquire to first obtain their NNCSS - VoIP Succession CSE 1000 Rls. 2.0 or the VoIP Succession 1000/1000M Rls. 3.0 installing & maintenance certification. as a result, an extra greater problematic version of the Succession 1000/1000M Rls. three.0 examination should live efficaciously achieved to achieve this certification.

within the IT trade, certifications are a fashion to validate an individual's advantage within a exact area. The above Nortel IP Telephony certifications are probably the most materiel that may array the capabilities of an IP Telephony assist professional. These certifications couldn't substitute years of industry event, however they Do deliver the foundation to uphold and exploit Nortel Voice over IP solutions.

The next tip will talk about Nortel's Design IP Telephony certification music.

Richard Parsons (CCIE#5719) is a manager of skilled capabilities for Callisma Inc., a totally owned subsidiary of SBC. He has constructed a superb groundwork in networking ideas, advanced troubleshooting, and monitoring in areas akin to optical, ATM, VoIP, routed, routing, and storage infrastructures. loaded resides in Atlanta GA, and is a graduate of Clemson institution. His legacy includes senior and predominant consulting positions at international network features, Lucent, and Callisma.


Bel Fuse (BELFB) this drop 2018 revenue conference convoke Transcript | killexams.com existent Questions and Pass4sure dumps

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

picture source: The Motley fool.

Bel Fuse (NASDAQ:BELFB)this autumn 2018 earnings convention CallFeb. 21, 2019 11:00 a.m. ET

Contents:
  • organized Remarks
  • Questions and solutions
  • name participants
  • organized Remarks:

    Operator

    first rate day, and welcome to the Bel Fuse Inc. fourth quarter and full-year 2018 results conference name. modern day convention is being recorded. at present, i want to exhibit the convention over to Mr.

    Dan Bernstein, president and chief executive officer. delight sprint ahead, sir.

    Dan Bernstein -- President and Chief govt Officer

    thank you, Allison. becoming a member of me on the title nowadays is Craig Brosious, their vice president of Finance; and Lynn Hutkin, their director of fiscal reporting. earlier than they start the call, i might fancy to anticipate Lynn to sprint over the secure harbor remark. Lynn?

    Lynn Hutkin -- Director of fiscal Reporting

    thank you, Dan. decent morning, everybody. before they start, i might fancy to read here secure harbor statement. except for historic suggestions contained on this call, the concerns discussed on this title corresponding to statements related to expected increase from the business's distribution channel, the results of the ERP system implementation and different high-quality industry and increase traits are forward-searching statements as described below the inner most Securities Litigation Reform Act of 1995 that involves dangers and uncertainties.

    exact effects could fluctuate materially from those projections. among the factors that might trigger genuine consequences to vary materially from such statements are: the market considerations facing their purchasers; the continuing viability of sectors that count on their products; the outcomes of company and economic conditions; difficulties associated with integrating currently obtained agencies; means and supply constraints or difficulties; product building, commercialization or technological difficulties; the regulatory trade ambiance; dangers associated with exotic currency; uncertainties associated with prison proceedings; the market's acceptance of the business's modern items and competitive responses to these modern products; the influence of alterations to U.S. change and tariff policies; and the risk elements exact sometimes within the company's SEC stories. In simple of the hazards and uncertainties, there may furthermore live no assurance that any forward-looking statement will, in fact, exhibit to live proper.

    We undertake no responsibility to update or revise any ahead-looking statements. They may additionally furthermore talk about non-GAAP effects throughout this convoke and reconciliations of their GAAP consequences to non-GAAP effects were protected in their liberate. And simply earlier than turning the title back to Dan, I simply desired to supply each person a heads up that their EBITDA reconciliation table in their accustomed release became fallacious. there were errors in that desk and a brand modern release is popping out.

    So delight fire that introductory desk. So it truly is the third table, which is on web page 7 of the liberate.

    Dan Bernstein -- President and Chief govt Officer

    thanks, Lynn. earlier than going throughout the financials, i want to provide a short update on how the companies did from an operational standpoint this quarter and what they observe going ahead. usual, we're very completely satisfied that they closed the 12 months with a different tenacious quarter, bringing their 2018 sales to $548 million, their larger revenue year for the understanding that 2015. extra importantly, their net income for the year of $21 million become the highest in over a decade.

    revenue totality the way through the fourth quarter were $142.7 million, up 19% from the fourth quarter of 2017 with double-digit growth in each and every of the 3 leading product lines. Their backlog of orders remained mighty at $171.2 million at December 31, 2018, a tower of 17% from a 12 months in the past. The enhance in backlog is furthermore considered across every of their main product companies, which is a righteous barometer for different future increase. and searching via at the replete 12 months.

    Our Magnetic solutions neighborhood closed the 12 months with $24.4 million enhance in sales over 2017 stages led by lofty demand for their built-in connector modules that are used in next-technology switching functions. revenue of their signal Transformer items acquire been additionally potent perquisite through 2018 as modern courses with clinical and industrial purposes moved into replete production. they now acquire furthermore increased the presence of their magnetic items via their distribution channels, which add to the 12 months-over-12 months sales growth. The backlog of orders from magnetic items grew by way of $9.7 million or 28% enhance for the understanding that the 2017 yr-end.

    Our Connectivity solutions neighborhood had yr-over-year revenue increase of $sixteen.four million. Their Cinch enterprise expanded profits via $8.2 million compared to 2017 led via mighty demand for optical and copper products utilized in encryption, communication and threat detection radar applications. Their Stewart passive connectors additionally saw boost in income of $8.2 million from 2017 as better financial conditions in the structure industry led to lofty demand for their premise wiring customs throughout the year. The Cinch and Stewart enterprise furthermore capitalize from wonderful increase in earnings through their distribution channel in 2018.

    average, the backlog of orders for their Connectivity products grew by using $7.8 million, or 16%, in view that 2017 12 months-conclusion stages. Their power options and insurance policy community had a turnaround yr as revenue boom of $15.8 million from 2017 led this community to its first 12 months of sales increase when you account that 2015. with the exception of the consequences of their NPS divestiture, sales for this group were up $21 million or 14% from closing 12 months, pushed by way of continued demand for their power supplies in diversity of information core functions. sales of their DC to DC and circuit insurance policy products furthermore grew in 2018, offset by using a decline favorite for their custom modules.

    The backlog of their orders for their vigour solutions and insurance policy community is up $7.1 million or eleven% from 2017 yr-conclusion levels. From a profitability standpoint, overseas trade righteous points and a righteous adjustment draw the transition tax out to mitigate the larger labor and fabric charges that impacted their bottom line this yr. They proceed to hang pricing company as they labor through their higher cost stock on end. concerning the tariffs that had been implemented in 2018, they assess that about 10% of their consolidated annual revenues are at the minute impacted.

    At this element, the bulk of these charges acquire been handed along to their customers in the shape of invoice can charge. They proceed to monitor the situation carefully as they fashion the tentative March 1 time confine for the U.S. accomplishing a pretty righteous cope with China in totality event extra increases on existing tariffs. typical, they abide cautiously confident with the continued income boom and profitabilities as they enter 2019.

    And with that, i would flip it over to Craig to dash in the course of the fiscal replace.

    Craig Brosious -- vice president of Finance

    Thanks, Dan. To supply a quick recap on income. revenue during the fourth quarter were $142.7 million. through geographic segment, North america earnings acquire been $70.3 million, Asia income were $49.1 million and Europe acquire been $23.3 million.

    with the aid of product neighborhood, Connectivity solutions income had been $46.four million, Magnetic solutions income were $forty eight.6 million and vigour options and insurance map revenue were $47.7 million. raw profit margin expanded to 21.3% in the fourth quarter of 2018 as in comparison with 18.5% within the fourth quarter of 2017 as incremental earnings in 2018 ended in more suitable fastened can permeate absorption offsetting larger labor expenses totality over the yr. moreover, their raw earnings margin totality through the fourth quarter of 2017 acquire been impacted through inventory-related costs totaling $2 million in connection with keeping their stock on the lower can permeate or net realizable cost. Their selling, commonplace and administrative expenses were $22.2 million or 15.6% of income as in comparison with $21.1 million or 17.6% of income in the fourth quarter of 2017.

    while the increase in SG&A costs totality the way through the 2018 length $900,000 pertains to a decline in market cost of their COLI policies, which changed into in accordance with the typical inventory market recreation during the fourth quarter of 2018. they now acquire already began to peer this reverse in 2019. different offsetting components that affected that the variance in the fourth-quarter durations had been better legal and expert charges of $800,000 offset by using a lessen in unhealthy debt cost of $500,000 and a discount in depreciation and amortization of $four hundred,000. On a go-ahead groundwork, they might predict SG&A to dash between $20 million and $21 million per quarter within the proximate time period, barring any huge fluctuations in exotic currency echange.

    because of these factors, they generated earnings from operations of $8 million in the fourth quarter of 2018 as in comparison to $1 million within the fourth quarter of 2017. pastime expense changed into -- i'm sorry, $1.4 million in the fourth quarter of 2018, down $900,000 from the identical duration closing yr. in case you uphold in mind, they refinanced their credit agreement in the fourth quarter of 2017, which ended in an acceleration of deferred financing cost amortization of $1 million during the remaining year's fourth quarter. Their provision for profits taxes became $2.four million for the fourth quarter of 2018 compared to $19.2 million totality through final year's fourth quarter.

    the supply for revenue taxes perquisite through the fourth quarter of 2018 was unfavorably impacted via taxes on international salary, the GILTI tax, partially offset by a subside within the U.S. tax cost from 35% to 21% in 2018. the availability for revenue taxes in 2017 era included an $18 million impact from the U.S. Tax Cuts and Jobs Act, which become enacted on December 22, 2017.

    profits per share for category a common shares was $0.31 per share in the fourth quarter of 2018 as compared with a loss of $1.sixty six per share in the fourth quarter of 2017. earnings per share for class B general shares was $0.33 per share within the fourth quarter of 2018 as compared with the exigency of $1.seventy four per share in the fourth quarter of 2017. On a non-GAAP groundwork, which excludes sure peculiar and different nonrecurring items, EPS for category A shares become $0.37 per share in the fourth quarter of 2018 as compared with the loss of $0.09 per share in the fourth quarter of 2017. On a non-GAAP groundwork, EPS for class B shares turned into $0.39 per share in the fourth quarter of 2018 as in comparison with a exigency of $0.10 per share within the fourth quarter of 2017.

    And now i would fancy to sprint through some stability sheet and cash circulation gadgets. Their money and cash equivalents equilibrium at December 31, 2018, changed into $fifty three.9 million, a lessen of $15.4 million from December 31, 2017. perquisite through 2018, they made payments of $9 million towards their astonishing debt steadiness. They furthermore used cash for capital charges of $11.6 million, dividend funds of $3.3 million and hobby funds of $four.8 million.

    money owed receivable were $ninety one.9 million at December 31, 2018 as compared with $78.8 million at December 31, 2017. Days income striking acquire been 59 days at December 31, 2018, compared to 60 days at December 31, 2017. The boost in debts receivable stability changed into generally because of the bigger revenue volume within the fourth quarter of 2018 as compared to the fourth quarter of 2017. Inventories were $120.1 million at December 31, 2018, up $12.three million from December 31, 2017.

    In January of 2018, they adopted the modern income cognizance regular, which hastens the timing during which they earnings become identified and the corresponding liberate of comprehensive items from their stock equilibrium concerning items held at customer control hubs. except for the results of this adoption, their stock stability would acquire elevated by $23.4 million from December 31, 2017, essentially uncooked materials and work-in-growth in keeping with the enhance well-known for their products in 2018. accounts payable had been $fifty six.2 million at December 31, 2018, up $8.2 million from its degree at December 31, 2017 because of the raise in raw material purchases. Bel's total fanciful debt turned into reduced with the aid of $744,000 during the fourth quarter, bringing the equilibrium down to $116 million as of December 31, 2018, aside from deferred financing cost.

    ebook cost per share, which is calculated as stockholders' equity divided by way of their combined A and B classes of typical inventory impressive, become $14.39 per share at December 31, 2018 as in comparison to $13.13 per share at December 31, 2017. And now i want to exhibit the title returned to Dan and open the convoke for questions.

    Dan Bernstein -- President and Chief government Officer

    yes. Do they open up the demand questions, please, Allison? 

    Questions and answers:

    Operator

    actually, sir. [Operator instructions] they are able to now purchase their first question from Sean Hannan from Needham & enterprise. delight sprint ahead, sir.

    Sean Hannan -- Needham and enterprise -- Analyst

    yes. Thanks. respectable morning, everyone. Dan, i used to live looking to observe if I might anticipate you might provide us with a exiguous bit of detail across the phase.

    i Do know you offered some on your prepared feedback. can you in totality probability find into a bit bit extra specificity when it comes to how had been you sentiment with each of these section nowadays and the actions they ramp perquisite here within the first quarter and in '19. and perhaps how that may additionally acquire trade or could live different versus what you were expecting probably just a brace of months in the past? Any perception there could live very effective. Thanks.

    Dan Bernstein -- President and Chief govt Officer

    adequate. Of path, totality of their product businesses and totality of the subdivisions inside the product corporations, a majority, i would say, 80% of totality were very robust. they now acquire one community, is the Modular group and the DC to DC neighborhood out of Italy which acquire some tremendous clients that they misplaced, but that hasn't been the relaxation to Do with the market conditions simply on account of the situation with these clients. So ordinary everything has been, as you live awake of, extraordinarily fine.

    Going into this quarter and subsequent quarter, January become a very -- they saw a tenacious January, and once again, they suppose they Do not observe any alterations within the first quarter. The handiest concerns that they Do acquire is there are some IC businesses that are seeing some softening in the market and they Do hear some rumblings that there may live too a lot inventory in the pipeline. but to this point it has not affected their revenue or backlog. So again, it's why I account we're a bit wonderful for the first quarter and for instance, I suppose proximate out after that.

    Sean Hannan -- Needham and company -- Analyst

    adequate. objective ample. Now as they look into the power neighborhood, it is definitely always a topic on each and every name. there's a whole lot that you've done when it comes to correcting the nice concerns from one of the vital acquisitions you've got taken on, there's a mighty deal you could acquire been doing to step-up executions, plenty that you acquire executed in incrementally successful modern designs and into modern programs some of which has been getting some momentum.

    and that i suppose you said that a bit bit earlier today. What extra may silent they anticipate within the trajectory of these organizations? Is there the relaxation within the history that's incrementally being labored down or is obtainable a bogey that might accelerate up the boom trajectory that you're now atmosphere into today? Or how should silent they account about how this continue to enhance as a product section for you? Thanks.

    Dan Bernstein -- President and Chief govt Officer

    good enough. So the punch community, again, as they brought up over the ultimate two or three years, they confidence very strongly that has the best boom expertise for Bel from a accurate-line standpoint. On the power, they did acquire is after they acquired the company previous administration truly failed to center of attention on pleasant and customer service. And it took us a very long time to exchange that; a, first change their manufacturing unit then exchange the client opinion, and over the last 18 months, they now acquire totality their purchasers are back and believe Bel to live a power corporation.

    I feel two issues that they now acquire achieved that they now acquire changed these days. One became, I consider, as they acquire been so desperate for earnings, they took a shotgun approach and really Put totality check on their R&D community without getting the ilk of effects that they would like. So what we've performed is, truly long past from much greater chosen fashion of what consumers you exigency to deal with, how they meet into us and should they live long-time era shoppers? With that said, they are streamlining their R&D community because they will not acquire to sprint with the southbound method, they comprehend what precisely engineers they deserve to pilot these products as they circulate ahead. the key difficulty now could live that they Do acquire two or key key customers that may sprint anywhere from $eight million to $12 million, $13 million.

    And once we're talking about statistics middle-category of customer, they Do acquire sizable customer classification of valued clientele. again, those fluctuate very sizable from a earnings standpoint. once more, however, they Do think that we've located ourselves much more within the market, and currently I feel they now acquire 90 NDA signed on high-effectivity vehicles and we're starting to observe that enterprise sprint from $three million to $5 million. So we're hoping that would double once more, offers us a lot more diversification, and they are working with different information center classification of customers.

    So they find that greater assorted. So again, they are silent taking pictures. Their goal has totality the time been to find vigour to that consistent 10% increase over a two to three-12 months period.

    Sean Hannan -- Needham and enterprise -- Analyst

    good enough. that's beneficial. and then closing query perquisite here. just to observe if i will live able to find some standpoint round a customer of yours without detain or ultimately.

    Huawei, I recall you might live now not necessarily even a 5% consumer, but are you able to focus on how Do they play into your enterprise traditionally? And is there the relaxation that they should silent account of thinking about that relationship or income technology and maybe by some means tied to them on a go-forward groundwork? Thanks.

    Dan Bernstein -- President and Chief executive Officer

    neatly, I suppose, again, being a chinese language business, I think they are inclined to sprint along with chinese providers in China. i know, for instance, they offered their punch provide neighborhood to Emerson about six years ago, and now former Huawei individuals acquire their own punch give company. So they know it's a troublesome nut to crack. They Do some ICM enterprise, however no longer vast in any respect.

    And for us, it's going to live a tenacious advantage as a result of they think people fancy Nortel, Cisco should silent prefer up the company that they're losing. So i Do know there are sure nations, Czech Republic, even Canada and the U.S. how they view Huawei going ahead. And that they cannot buy materiel from Huawei for 5G, they will doubtless sprint with -- I failed to imply Nortel, I anticipate for forgiveness, Nokia, that Nokia and Cisco will likely elect up that slack and might live Alcatel, and these multinational non-chinese language purchasers they Do sizable quantity of industry with them.

    So we're hoping that their industry should silent increase as more and more 5G is delivered.

    Sean Hannan -- Needham and company -- Analyst

    Very first rate. Thanks so tons, folks.

    Operator

    [Operator instructions] And they will now purchase a question from Hendi Susanto from G. analysis. delight sprint forward.

    Hendi Susanto -- G. analysis -- Analyst

    first rate morning. Dan, you commute to China a mighty deal. How Do you signify your China market now? How different is it in comparison to a typical 12 months?

    Dan Bernstein -- President and Chief executive Officer

    We at totality times -- for us -- totality over the realm, I imply, Europe and China there may live so a lot dubiety and how they confidence in Donald Trump and the job he's doing. there's giant amount of anxiousness. For us again, for the China market, or not it's always been very complicated to demolish into that market as a result of the pricing parameters that you've got promoting to, again, a chinese language consumer. although, a righteous component can live 35% of their sales sprint to China, but it surely goes throughout the CEM fancy the Flextronics or Hon Hai, Foxconn, and those are non-chinese groups.

    youngsters, they Do -- they are starting to observe more americans stare at China in a sever easy. They recognize the ODMs in Taiwan, they acquire majority of their production in China. They at the minute are poignant a few of that creation lower back into Taiwan. They observe other multinationals relocating products round to find across the tariffs.

    So when you've got production in Malaysia, employ that for totality items coming to the States after which you employ your China production to sprint into Europe and the a long way East market. but once again, no one likes dubiety and that without query with the tariffs there's giant amount of uncertainties and that's not first rate for anyone.

    Hendi Susanto -- G. research -- Analyst

    got it. after which Dan, given solid income growth and your backlog boom in 2018 and existing ERP implementation, how a righteous deal development in raw margin and working margin they should anticipate in 2019?

    Dan Bernstein -- President and Chief executive Officer

    i will depart that to my accounting neighborhood here.

    Craig Brosious -- vice president of Finance

    yes. I account assuming the within your budget sales increase that we're expecting, qualify income increase, I believe they acquire some leverage means to movement the raw margin up to maybe a point, aspect and a half. once more, lots of their construction costs are primarily based in the -- in China and counting on which approach the trade agreements go, it may acquire an consequence on the change fees that they should deal with on the can permeate of that -- on the labor costs, exceptionally. So barring any massive moves in these change charges, we've opportunities to extend margins a bit bit.

    Hendi Susanto -- G. research -- Analyst

    after which a further question on charge. So I think Bel Fuse is coping with enhance in labor charge, and that i suppose that has been there for a long time after which you were mitigating or taking movements or improved your labor charge. after they sprint through fancy 2019, when can they examine on an apple-to-apple 12 months-over-12 months assessment in regards to the labor can charge? And fancy how -- and then live sure you live in a position to quantify how an Awful lot labor permeate become?

    Craig Brosious -- vice chairman of Finance

    I believe they -- to find to an apples-to-apples comparison, they are able to likely should find within the third quarter of this year because they had permeate raises going into impact within the first and second quarters of 2018. So I feel as soon as they find to the third quarter, they find some low cost comparatives.

    Lynn Hutkin -- Director of fiscal Reporting

    The most efficacious aspect to add there's, in 2019, we're furthermore experiencing elevated labor permeate in Mexico so that you can affect the 2019 length, however changed into not there perquisite through the 2018 period. So they acquire that as smartly.

    Hendi Susanto -- G. analysis -- Analyst

    adequate. and then the majority of the tariff cost has been passed to clients. can you quantify how a mighty deal has been handed and what's next?

    Dan Bernstein -- President and Chief executive Officer

    I account it's been about $7.eight million, in that latitude.

    Lynn Hutkin -- Director of fiscal Reporting

    In 2018, it become about $2.four million, in total for 2018, in order that become a partial -- that was a partial 12 months.

    Craig Brosious -- vice chairman of Finance

    So fancy Dan had mentioned previously, most of their sales as a minimum coming out of China don't become without detain into the U.S. So we're not enormously impacted through the tariffs. So they acquire been capable of -- basically $2.5 million or in order that they needed to add.

    Hendi Susanto -- G. analysis -- Analyst

    good enough. acquired it. thanks.

    Operator

    [Operator instructions] It appears there aren't any additional questions. Mr. Bernstein, i would fancy to exhibit the convoke back to you for any additional or closing remarks.

    Dan Bernstein -- President and Chief govt Officer

    thank you for joining us nowadays, and they look to talking to you sooner or later. thanks to your time.

    Operator

    [Operator signoff]

    length: 29 minutes

    call members:

    Dan Bernstein -- President and Chief government Officer

    Lynn Hutkin -- Director of monetary Reporting

    Craig Brosious -- vp of Finance

    Sean Hannan -- Needham and enterprise -- Analyst

    Hendi Susanto -- G. research -- Analyst

    greater BELFB analysis

    this article is a transcript of this convention convoke produced for The Motley fool. while they try for their foolish premier, there could live mistakes, omissions, or inaccuracies during this transcript. as with totality their articles, The Motley fool does not assume any responsibility for your employ of this content material, and they strongly cheer you to Do your personal analysis, together with listening to the convoke yourself and analyzing the business's SEC filings. delight observe their phrases and conditions for additional details, together with their mandatory Capitalized Disclaimers of liability.

    10 shares they fancy enhanced than Bel FuseWhen investing geniuses David and Tom Gardner acquire a stock tip, it can pay to hear. in spite of everything, the e-newsletter they've dash for over a decade, Motley fool stock marketing consultant, has quadrupled the market.*

    David and Tom simply printed what they correspond with are the 10 finest stocks for investors to buy perquisite now... and Bel Fuse wasn't one in totality them! it's commandeer -- they think these 10 stocks are even more advantageous buys.

    See the ten stocks

    *stock marketing consultant returns as of January 31, 2019

    Motley fool Transcribing has no position in any of the shares mentioned. The Motley idiot has no position in any of the shares mentioned. The Motley fool has a disclosure policy.


    Bel Fuse Inc. (BELFB) CEO Daniel Bernstein on this autumn 2018 consequences - income title Transcript | killexams.com existent Questions and Pass4sure dumps

    No result discovered, are trying modern keyword!Bel Fuse Inc. (NASDAQ:BELFB) this drop 2018 results profits convention convoke February 21 ... demand for their punch substances in diversity of data middle purposes. earnings of their DC to DC and circuit ...

    While it is difficult errand to pick solid certification questions/answers assets regarding review, reputation and validity since individuals find sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets as for exam dumps update and validity. The greater Part of other's sham report objection customers arrive to us for the brain dumps and pass their exams cheerfully and effortlessly. They never deal on their review, reputation and character because killexams review, killexams reputation and killexams customer certainty is imperative to us. Extraordinarily they deal with killexams.com review, killexams.com reputation, killexams.com sham report grievance, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off random that you observe any untrue report posted by their rivals with the title killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protestation or something fancy this, simply recall there are constantly terrible individuals harming reputation of righteous administrations because of their advantages. There are a mighty many fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams questions, killexams exam simulator. Visit Killexams.com, their sample questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.

    Back to Braindumps Menu


    000-137 free pdf | M9560-760 braindumps | TK0-201 brain dumps | OG0-9AB questions and answers | HP2-E15 existent questions | 1Z0-567 exercise test | 000-318 pdf download | 00M-230 cheat sheets | CISM mock exam | A2040-956 free pdf download | 650-575 exercise Test | 1Z0-547 bootcamp | M2010-719 examcollection | 650-316 exercise test | 270-411 free pdf | 77-883 exercise test | 1Z0-325 sample test | 1Z0-599 braindumps | 000-913 exam prep | 000-005 exercise questions |


    Ensure your success with this 920-106 question bank
    Is it accurate to whisper that you are searching for Nortel 920-106 Dumps of existent questions for the NNCSS SYMPOSIUM convoke center Exam prep? They give as of late refreshed and incredible 920-106 Dumps. Detail is at http://killexams.com/pass4sure/exam-detail/920-106. They acquire gathered a database of 920-106 Dumps from existent exams on the off random that you exigency to can enable you to assemble and pass 920-106 exam on the first attempt. Simply set up together their and unwind. You will pass the exam.

    killexams.com lofty value 920-106 exam simulator will live facilitating for their customers for the test steering. totality vital functions, exercise questions and definitions are highlighted in 920-106 brain dumps pdf. Gathering the records in one region will live a existent time saver and makes you confident for the NNCSS SYMPOSIUM convoke center exam within a brief time span. The 920-106 exam provides key points. The killexams.com with pass4sure dumps permits to memorize the essential questions or concepts of the 920-106 exam At killexams.com, they proffer absolutely verified Nortel 920-106 exercise questions that are the satisfactory for Passing 920-106 exam, and to induce certified with the assistance of 920-106 braindumps. It is a righteous option to accelerate your career as a specialist within the Nortel Technology. they are pleased with their character of supporting humans pass the 920-106 exam of their first attempt. Their success fees at intervals the past 2 years were sure enough gorgeous, because of their ecstatic shoppers currently ready to boost their career at the quick lane. killexams.com is the primary preference among IT specialists, above totality those are trying to climb up the hierarchy of qualifications faster in their respective organization. Nortel is the enterprise leader in info generation, and obtaining certified will live assured to succeed with IT careers. they acquire an approach to assist you with their extravagant best Nortel 920-106 brain dumps.

    killexams.com helps millions of candidates pass the exams and find their certifications. They acquire thousands of successful reviews. Their dumps are reliable, affordable, updated and of really best character to overcome the difficulties of any IT certifications. killexams.com exam dumps are latest updated in highly outclass manner on regular basis and material is released periodically. Latest killexams.com dumps are available in testing centers with whom they are maintaining their relationship to find latest material.

    The killexams.com exam questions for 920-106 NNCSS SYMPOSIUM convoke center exam is mainly based on two accessible formats, PDF and exercise questions. PDF file carries totality the exam questions, answers which makes your preparation easier. While the exercise questions are the complimentary feature in the exam product. Which helps to self-assess your progress. The evaluation appliance furthermore questions your decrepit areas, where you exigency to Put more efforts so that you can better totality your concerns.

    killexams.com recommend you to must try its free demo, you will notice the intuitive UI and furthermore you will find it very simple to customize the preparation mode. But Make sure that, the existent 920-106 product has more features than the crucible version. If, you are contented with its demo then you can purchase the actual 920-106 exam product. Avail 3 months Free updates upon purchase of 920-106 NNCSS SYMPOSIUM convoke center Exam questions. killexams.com offers you three months free update upon acquisition of 920-106 NNCSS SYMPOSIUM convoke center exam questions. Their expert team is always available at back cessation who updates the content as and when required.

    killexams.com Huge Discount Coupons and Promo Codes are as under;
    WC2017 : 60% Discount Coupon for totality exams on website
    PROF17 : 10% Discount Coupon for Orders greater than $69
    DEAL17 : 15% Discount Coupon for Orders greater than $99
    DECSPECIAL : 10% Special Discount Coupon for totality Orders


    920-106 Practice Test | 920-106 examcollection | 920-106 VCE | 920-106 study guide | 920-106 practice exam | 920-106 cram


    Killexams LOT-803 exercise test | Killexams C9010-262 questions answers | Killexams 9A0-381 sample test | Killexams 000-918 existent questions | Killexams P2170-035 exam prep | Killexams MSC-321 study guide | Killexams C2090-603 exam prep | Killexams 1Z0-932 cram | Killexams 310-875 exercise questions | Killexams CWNA-107 questions and answers | Killexams 1Z0-439 exercise exam | Killexams 000-651 pdf download | Killexams NCPT existent questions | Killexams 000-451 exercise test | Killexams MSC-331 questions and answers | Killexams ST0-086 examcollection | Killexams 1Z0-100 existent questions | Killexams HP2-H65 exercise test | Killexams 70-565-VB bootcamp | Killexams 000-N19 test questions |


    killexams.com huge List of Exam Braindumps

    View Complete list of Killexams.com Brain dumps


    Killexams HP2-E46 free pdf | Killexams SK0-004 existent questions | Killexams HP0-092 exercise test | Killexams 00M-194 pdf download | Killexams 000-208 exercise questions | Killexams APA-CPP study guide | Killexams 050-644 test prep | Killexams HP2-E15 dumps questions | Killexams MB2-527 exercise Test | Killexams HP2-B121 examcollection | Killexams P2170-036 questions and answers | Killexams 3I0-012 test prep | Killexams C2090-625 free pdf | Killexams 700-270 exercise questions | Killexams MOS-A2K cheat sheets | Killexams 310-065 exam questions | Killexams 000-976 cram | Killexams PCCE test prep | Killexams LOT-915 exercise exam | Killexams 050-CSEDLPS test questions |


    NNCSS SYMPOSIUM convoke CENTER

    Pass 4 sure 920-106 dumps | Killexams.com 920-106 existent questions | http://coqo.com/

    Strongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference convoke Transcript | killexams.com existent questions and Pass4sure dumps

    Logo of jester cap with thought bubble.

    Image source: The Motley Fool.

    Strongbridge Biopharma plc  (NASDAQ:SBBP)Q4 2018 Earnings Conference CallFeb. 26, 2019, 8:30 a.m. ET

    Contents:
  • Prepared Remarks
  • Questions and Answers
  • Call Participants
  • Prepared Remarks:

    Operator

    Good morning, ladies and gentlemen, and welcome to the Strongbridge Biopharma Corporate Update and Fourth Quarter 2018 Earnings Conference Call. At this time, totality participants are in a listen-only mode. Later they will conduct a question-and-answer session and instructions will result at that time. (Operator Instructions) As a reminder, this convoke will live recorded.

    I would now fancy to interpolate your host for today's conference, Ms. Lindsay Rocco of Elixir Health Public Relations. You now may begin.

    Lindsay Rocco -- Investor Relations

    Thank you and righteous morning, everyone. They are pleased that you could associate us today for Strongbridge Biopharma's fourth quarter and replete year 2018 earnings conference call. Joining me from Strongbridge this morning are Matthew Pauls, President and Chief Executive Officer; Dr. Fred Cohen, Chief Medical Officer; and Brian Davis, Chief financial Officer.

    Before they begin, I would fancy to remind you that during this call, the Company will live making forward-looking statements that are subject to risks and uncertainties that may antecedent actual results to disagree from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the Company's sporadic and current event filings with the U.S. Securities and Exchange Commission.

    In addition, this presentation includes non-GAAP financial measures. This presentation is not intended to live a substitute for financial results presented in conformity with generally accepted accounting principles in the U.S. Investors and potential investors are encouraged to review the reconciliation of the pro forma financial measures included in the Company's earnings release. The most directly comparable GAAP information and a reconciliation between the non-GAAP and GAAP figures are included in the Company's fourth quarter 2018 earnings release, which has been furnished on shape 8-K.

    I will now circle the convoke over to Matthew Pauls.

    Matthew Pauls -- President and Chief Executive Officer

    Thank you, Lindsay. righteous morning everyone and thanks for joining us. For today's call, I'll open by providing a brief summary of their fourth quarter and replete year 2018 highlights and results. And then we'll circle the convoke over to Dr. Fred Cohen, their Chief Medical Officer, to debate the ongoing side III clinical development program for RECORLEV. Brian Davis, their Chief financial Officer, will then provide a financial overview. They will then open up the convoke for questions.

    With that, let me start by adage that Strongbridge had a tenacious fourth quarter from a clinical, commercial and financial perspective, which is a reflection of their momentum and overall success throughout the past year. As you will hear from the team today, their accomplishments in 2018 demonstrate the value of their rare disease strategy and acquire positioned us for future growth as they continue to identify, develop and commercialize distinguished treatments for rare diseases. Leveraging the momentum from last year, they entered 2019 with a focus on progressing the development of RECORLEV for the treatment of endogenous Cushing's syndrome.

    And getting into their most notable fourth quarter accomplishments, let's start with the Novo Nordisk transactions. In December, they significantly strengthened their equilibrium sheet with the sale of the U.S. and Canadian rights of MACRILEN to Novo Nordisk. As previously mentioned, a portion of the upfront cash payment of $145 million from Novo Nordisk to Strongbridge was used to repay totality outstanding debt. Other key terms from the transaction comprise that Strongbridge will receive royalties on MACRILEN sales through 2027. And in addition, Novo Nordisk purchased 5.2 million ordinary shares of Strongbridge at a purchase cost of $7 per share, resulting in raw proceeds of $36.7 million.

    Another distinguished key strategic term of the transaction is that Novo Nordisk will fund Strongbridge's 23-person rare endocrine commercial territory organization over the next three years to promote MACRILEN in the United States. This aligns with the Company's objective to maximize the potential of MACRILEN, while preparing for the potential regulatory approval of RECORLEV in endogenous Cushing's syndrome, a rare condition that's often treated by the identical endocrinologist that diagnose and deal adult growth hormone deficiency.

    Onto their rare neuromuscular franchise. KEVEYIS, their first commercial product, enabled us to build out a rare neuromuscular franchise, which continues to live a strategic pillar for the Company. They are committed to serving the needs of the primary sporadic paralysis, or PPP community, which is comprised of an estimated 4,000 to 5,000 currently diagnosed patients in the United States. As they prepare for the regulatory filing of potential launch of RECORLEV, there are many parallels and learnings that they acquire garnered from the KEVEYIS chance that they acquire and will continue to leverage across their business.

    Additionally, they believe that the undergo and erudition gained from launching KEVEYIS best positioned Strongbridge to acquire the rights to MACRILEN early last year, before selling the rights to Novo Nordisk at the cessation of the year. As Part of their life cycle management planning for KEVEYIS, they are executing on a number of initiatives with the primary objective of maximizing the value of KEVEYIS over time. They believe that by the cessation of 2019 or into early 2020 that they will live in a position to provide an update on their life cycle management progress.

    Our investment approach with KEVEYIS focuses on three key areas. Specifically, they are focusing their KEVEYIS commercial investment on, one, utilizing sophisticated data to identify physicians that deal PPP; two, fully leveraging their CareConnection patient services model; and three, engaging the PPP community through both patient advocacy, as well as targeted gregarious media. They stare forward to executing against their 2019 plans and believe that KEVEYIS will generate a positive contribution margin by the cessation of the first quarter of 2020.

    So with that I'll circle the convoke over to Dr. Fred Cohen, their Chief Medical Officer, to debate their clinical development progress for RECORLEV, which they believe continues to acquire the potential to live a first-line, first-choice therapy for patients with endogenous Cushing's syndrome.

    I will now circle the convoke over to Fred.

    Fredric Cohen -- Chief Medical Officer

    Thank you, Matt. righteous morning, everyone. As previously announced in the third quarter, the pivotal side III SONICS study of RECORLEV for the treatment of endogenous Cushing's syndrome met its primary endpoint, with urinary free cortisol or UFC confirmed (ph) as typical among 30% of the intent to deal population at the cessation of the six-month maintenance phase.

    Detailed initial results from the SONICS study were presented in October at the European NeuroEndocrine Association Annual Meeting, with additional data presented at the European Network for the study of Adrenal Tumors Annual Meeting in November. These analyses illustrated the propitious effects of RECORLEV on hypercortisolism and its comorbidities, particularly sustained improvements in markers of cardiovascular risk, such as LDL-cholesterol, hemoglobin A1C and cadaver weight.

    Further SONICS results from the cessation of maintenance analyses are planned for presentation at the International Pituitary Congress and the Endocrine Society's Annual Meetings in late March, and at the American Association of Clinical Endocrinology Meeting in April. These results will highlight additional benefits of RECORLEV on the signs and symptoms of hypercortisolism.

    Additionally, submission of a manuscript of the primary efficacy and safety data from SONICS to a peer-reviewed journal is anticipated in the first half of 2019. One-year data from the completed SONICS study are expected to live available in the first half of 2019. These data will comprise findings from the six-month extended evaluation phase, which is primarily intended to characterize the long-term safety, tolerability and benefit-risk profile of RECORLEV.

    From a regulatory standpoint, a ilk C meeting with the FDA is planned within this quarter to hunt guidance on the path forward to obtain marketing approval for RECORLEV in the United States, and that process is on track. They anticipate providing an update in the second quarter.

    Finally, the receipt of top line results from the side III LOGICS study remains on track for the fourth quarter of 2019. As a reminder, LOGICS is a double blind crucible with no planned interim analyses prior to the receipt of these anticipated results.

    And with that, I will now circle the convoke over to Brian Davis for a financial overview.

    A. Brian Davis -- Chief financial Officer

    Thank you, Fred. Their press release hold details of their financial results for the fourth quarter and replete year 2018. Rather than read totality of those details, my comments will center on a few highlights.

    As famed in the press release, their guidance for KEVEYIS revenues in 2019 is in the $18 million to $20 million range. They acquire significantly improved their financial and strategic flexibility as a result of the cash proceeds and anticipated future payments from their transactions with Novo Nordisk, as well as the repayment in replete of their outstanding debt. They ended 2018 with $122.5 million of cash, cash equivalents and no outstanding debt. As for cash runway, they believe the combination of their existing cash resources, anticipated KEVEYIS revenues and payments from Novo Nordisk, as well as the continued prudent management of their operating expenses will provide enough capital to uphold their operations, at least through the first quarter of 2021.

    And Catherine, with that, they are now ready to open up the convoke for questions.

    Questions and Answers:

    Operator

    (Operator Instructions) And their first question comes from Esther Hong with Janney. Your line is open.

    Esther Hong -- Janney -- Analyst

    Hi, righteous morning. Thanks for taking my questions. So with respect to the ilk C FDA meeting over RECORLEV, can you provide additional details on your expectations, and then, any potential logistics regarding accelerator approval? And then the second question is, any updates on industry development plans in 2019? Thanks.

    Matthew Pauls -- President and Chief Executive Officer

    So Esther, this is Matt. Thank you for the questions. Let me purchase them in reverse order. With esteem to industry development, they obviously don't remark on any industry development-related projects that they may live working on. I Do think that their history here at Strongbridge -- as they continue to build the Company is that they are energetic in looking at opportunities and that continues. And that's totality I'll whisper on that front. I will acquire Dr. Cohen remark on the ilk C regulatory process and timing.

    Fredric Cohen -- Chief Medical Officer

    Sure. So as I've just -- they Do map to acquire the discussion with the FDA in the first quarter of this year, and then following digestion of that and then any clarifying dialog they exigency to acquire with the FDA, they map to update investors by the second quarter with the path forward, as they said. In terms of their foundation case, just to reiterate, they are anticipating that the FDA will pilot us toward the exigency for both the replete SONICS as well as the replete LOGICS study for being in hand and included within NDA. Again, that's the foundation case. The upside case for us that they believe is supported with the unmet medical need, the way that SONICS was designed in terms of using a surrogate endpoint that's been established, and the precedent within this division of allowing approval on the basis of the single open label study, they believe that there is an upside case where there could live an accelerated pathway toward the filing, where they foundation it primarily just on the SONICS, to your point around accelerator approval. Again, they Do think that the dialog that we're anticipating with the FDA in this quarter will Make that pathway transparent for us and then we'll update you guys accordingly.

    And with esteem to timing, that's just so -- in the expedited or accelerated upside case, clearly they would live working difficult to find it -- find the NDA filed as quickly as possible, probably realistically why they would custody for to acquire it filed by the cessation of the year, at the cessation of 2019, it probably would live more fancy an early 2020-ish. More details to arrive on that, obviously, as they acquire more clarity. In the foundation case, it would live about a year later than that. I hope that helps.

    Esther Hong -- Janney -- Analyst

    It does. Great, thank you.

    Fredric Cohen -- Chief Medical Officer

    You are welcome.

    Operator

    Thank you. And their next question comes from Annabel Samimy with Stifel. Your line is open.

    Nick Rubino -- Stifel -- Analyst

    Good morning, everyone. This is Nick Rubino on for Annabel Samimy. Thanks for taking their question. First, how the efforts to educate physicians on titration helped patient retention. Are you silent seeing attrition due to the side effects and how Do you observe those dynamics playing out 2019 and beyond? And then second with the one-year SONICS, you had mentioned the safety pieces, but are they getting efficacy measures as well? And then, if I can just sneak in a quick quick one, with the MACRILEN revenue numbers you reported this quarter, are those purely royalty revenues or did those comprise replete sales from October and November? Thanks.

    Matthew Pauls -- President and Chief Executive Officer

    Thanks for those questions, Nick. Let me give you a exiguous insight on the first question regarding KEVEYIS. They erudite a lot on the KEVEYIS fronts in 2018 regarding both KEVEYIS as well as primary sporadic paralysis. And one of the key learnings which you well said was around the need, often to sprint a exiguous bit lower and a exiguous bit slower in the titration period. And, I'll anticipate Dr. Cohen just to remark briefly on that. I think, they acquire some learnings from side III crucible and then from the clinical -- not just clinical instant -- in the clinical trial, but furthermore in the commercial employ too. So, Fred, Do you want to remark on that?

    Fredric Cohen -- Chief Medical Officer

    Yeah. Yeah, sure. Great. So one of the things that they erudite was that there are a significant minority of patients who experienced adverse reactions from the drug early on in the therapy. And one of them -- one of those reactions that's common is on -- a confusion on mental fog, if you will, that occurs. It's a ephemeral response to the drug until the brain can sort of equilibrate and become used to the drug. But when it occurs, it needs to live addressed, it needs to live managed, and the best way that they know how to manage it is by lowering the dose of the drug.

    Well, it took us a while, I think, number one, to recognize that this was a reaction that was responsible for some patients discontinuing from the drug. And once they did recognize that, they Put in position a progression of educational efforts aimed at physicians initially and then later direct-to-patient education and custody through the employ of, for example, patient ambassadors that acquire given their time generously to attend educate other patients. And so we're making mighty progress. I think, it's objective to whisper we've seen already changes in the way the titrations are going. And we've gotten feedback from patients who are now able to overcome the initial side-effects and acquire stayed on the drug, because they are seeing benefits from it in many cases. So, I hope that addresses that Part of that question.

    Nick Rubino -- Stifel -- Analyst

    Yes, that's great. Then, with regards to the --

    Matthew Pauls -- President and Chief Executive Officer

    Yes, the MACRILEN revenues during the fourth quarter were product sales by Strongbridge. There were no royalties in their revenues for the quarter.

    Fredric Cohen -- Chief Medical Officer

    Yes, there was furthermore a question you had about the 1-year RECORLEV data. So on the top line data that they will live sharing with you will comprise primarily safety data. But furthermore they did measure some efficacy data as well, including urine free cortisol, as well as those comorbidity markers. And I'm pretty sure we'll live sharing that with you at the time they release the top line results.

    Nick Rubino -- Stifel -- Analyst

    Alright. Great. Thank you guys.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, thanks for the questions.

    Operator

    Thank you. And their next question comes from Hartaj Singh with Oppenheimer & Company. Your line is open.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great, thanks. Thanks for the question and a righteous year. Just a brace of questions, Matt I've got. On your interactions with the FDA prior to this meeting, I assume you might acquire already submitted a sort of a briefing package and benevolent of there acquire been some interactions back and forth. Can you just give some color on, sort of, the gist of those interactions and what are some of the questions that maybe you're asking or FDA is wanting to live addressed prior to the actual meeting? And then a second question, just on KEVEYIS, to result up with the previous question. Matt, can you just give some color on, sort of, modern patients, continuing patients, what sort of -- how many patients are staying on drug, on average, just any color around what that dynamic is, because it seems that the drug is growing quarter-on-quarter. And then just your thoughts about that going forward. And then just a quick housekeeping question after that. Thank you.

    Matthew Pauls -- President and Chief Executive Officer

    Great, thank you Hartaj. So on the regulatory question related to RECORLEV. As a yardstick course for us, they don't remark on the interactions prior to having their final interpretation of the dialog. So more to arrive in the second quarter. And I think, Fred articulated well earlier what their foundation case assumptions are meeting both trials and the upside case around an accelerated potential approval, given the significant unmet exigency in Cushing syndrome, UFC being a stated accepted surrogate endpoint by the FDA, resoundingly positive, and they think compelling SONICS data. And then, in this division, in the review of Cushing's syndrome, single crucible approvals. So that's where we're at and we'll provide an update in the second quarter.

    And then with esteem to KEVEYIS -- and your question on KEVEYIS. So what they know is that there -- they are confident there are 4,000 to 5,000 patients currently diagnosed with PPP. They are seeing modern patients regularly arrive onto KEVEYIS. And they are doing a much better job, as Fred mentioned, with esteem to patient-to-patient interaction, patient-to-physician interaction, recommendations around maybe lower and slower titration or down titration. So they are seeing patients more often than not -- now abide on the drug through that benevolent of an interim period.

    And so, the sizable focus for us here is being smart and choiceful about their investment even with esteem to KEVEYIS, because it's distinguished for many reasons to try to drive KEVEYIS to profitability on a stand-alone basis as quickly as possible. And we're confident that we're on that path by the cessation of the first quarter of 2020. And parallel to that, given the fact that there are no other drugs really that are in development for the treatment of this ultra-rare genetic neuromuscular condition, PPP, they are working very feverishly and hard, as we've said previously, around life cycle management opportunities. They would custody for to acquire the chance to acquire more runway with KEVEYIS. So more to arrive by the -- probably by the cessation of the year, again, maybe into 2020 on their life cycle management plans. But this is a market that prior to us relaunching the drug really had no investment ever, was disorganized, unstructured. And we're confident that we're on the path to structuring it, organizing it and getting KEVEYIS to profitability, so that we're being smart and choiceful and sensible with esteem to their investment.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great. And Matt, that's mighty color. Just a follow-up on that. So roughly speaking, are you sort of seeing patients that are coming that are modern to KEVEYIS being equal to patients dropping off, or is there less of a drop-off, just what's the dynamic there between the modern and the continuing patients and the patients that are leaving, whether it's titration or for other issues?

    Matthew Pauls -- President and Chief Executive Officer

    So, they -- the trend is that more patients are staying on the drug than off. And that's based on the interventions, really in -- I guess in the back half of the third quarter and the fourth quarter by us, and of course to-date. So what we're -- the patient identification and identifying patients who are very motivated and physicians that are motivated and then providing the very tenacious even of uphold and service for them through that process, given the potency of KEVEYIS. I imply the drug really works. It really works. They are having success getting patients through that short -- I don't know -- for a four-to-six-week period-ish, that range. But it's upwards of eight weeks.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Got it. And then just one housekeeping question on -- just how to think about operating expenditures, sort of, going forward for the year, just any thoughts there? And again, thank you so very much.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, Hartaj. This is Brian, Hartaj. Thanks for that. So, on the cash basis, as I mentioned, we're looking at a runway that takes us through the first quarter of 2021. I think they acquire the capitalize of the Novo Nordisk subsidy coming online here in 2019 to offset the commercial application around MACRILEN. And so we'll acquire a exiguous transition working through Q1 to find down on a cash scorch basis. But they feel pretty comfortable in that low-to-mid teens region as they sprint forward. In fact, if you purchase that $122 million cash equilibrium and just by simple averaging over the subsequent nine quarters through the first quarter of 2021 that comes up to about $13.5 million. So a exiguous more in this year, reflecting the transition down, reflecting we've got some increased RECORLEV program expenses (inaudible) lofty water mark, if you will, for the RECORLEV program, because they acquire SONICS and LOGICS and OPTICS running simultaneously, but obviously SONICS expense is winding down now that the one-year data will live coming through. So again, enough cash to find us at least through the first quarter. And obviously, we'll acquire more definition on that as they sprint along as to how much more at least it can be.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great. And I really prize it. Thank you very much.

    Operator

    Thank you. And their next question comes from Liisa Bayko with JMP Securities. Your line is open.

    Liisa Bayko -- JMP Securities -- Analyst

    Hi, congratulations on the quarter. Just a brace of questions for me, mainly about KEVEYIS. So first of all, I want to whisper congratulations, I imply you've made this into a product that reached $20 million this year, which is certainly a lot higher than where you thought the product brace of years ago. They technically were only talking about $1 million. So it's obvious that you've done a tremendous job in creating this market. But again (ph) your guidance a exiguous bit, for this year, looks fancy $4.4 million is the benevolent of what you're coming off 4Q (ph). Your guidance of $18 million to $20 million implies a exiguous bit of slowing growth. So is that -- are patients adds silent happening at the identical rate or is that lower, are you having -- struggling to find more patients or is it based on -- basically from your comments, I'm thinking maybe less revenue per patient because of dose titration. What's the benevolent of dynamic with add indications or revenue per patient? How does that -- what's sort of underlying the guidance?

    A. Brian Davis -- Chief financial Officer

    Yes, this is Brian. So again, we're continuing the righteous news, is find patients. And they feel really righteous about the territory force they acquire in position and they're performing very strongly, as Matt indicated in his comments and in the prior answer. We've had a lot of learning in this market and working through how best not only to attract patients, but furthermore to retain patients. So they were conscious of the revenue attain that they Put out there, $18 million to $20 million and where we've arrive off of this year, we're going to live conservative in their approach, But the patient retention piece takes time and they think we're working through it.

    On the expense side, they acquire focused their investment and made decisions to subside the territories to attend Make sure they find to a positive contribution margin or a profitability standpoint for the product. They went from 21 down to 17 territories. They focused their marketing expenses to those -- really targeted toward the patient, in order to attend totality of the revenue expenses to line up. So, we'll uphold working through it, but they feel righteous about their capacity to not only hit this range, but furthermore to find this product to live one that's a profitable one. And as you pointed out at the beginning, it was a very challenging market to enter into. You're quite correct. Before they had acquired the drugs -- the drug, I should say, its sales had been less than $1 million in a year. So, yes.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, so Liisa, the other piece on that to note is, as I mentioned, in parallel, they are looking at life cycle management opportunities and we'll update the market probably by the cessation of the year or in early 2020. And if there are potential opportunities to extend the life and runway of KEVEYIS, they will obviously, probably revisit their investment strategy with esteem to the brand. But perquisite now, it is to find it to profitability as quickly as possible and to grow the top line, which they will Do both. And exiting the year, the low cessation of the range, we're tracking already to the low cessation of the range. So hopefully, there will live some -- even more enhanced or increased momentum as they sprint the year.

    Liisa Bayko -- JMP Securities -- Analyst

    Okay, objective enough. And then, I guess, as you stare longer-term, are you silent thinking this product is benevolent of easily a brace hundred million or Do you acquire some other benevolent of target in humor longer-term now that you've had more undergo selling the drug? Just thinking about how, benevolent of, directionally where they should live headed in terms of modeling. Thanks.

    A. Brian Davis -- Chief financial Officer

    I think -- this is Brian. I think, there's a brace of things there, Liisa, that really play into that. So one is the patient penetration. So they think we've got an chance and we're really just at the genesis stages of it in terms of patient penetration. Now Matt and Fred were taking a exiguous bit earlier about life cycle management opportunities, having a longer commercial runway will certainly allow us the chance to attain peak sales levels over a longer era of time that they acquire (inaudible). We're just operating with the current regulatory exclusivity. I think, the other piece that obviously plays into in this environment is around the cost of the drug. And I would note, they continue to live very cautious in their thinking around that. So we'll talk about pricing strategy, specifically, but we're very awake of the environment that we're in and we're going to act appropriately in that environment, and really try to Do totality they can to Make sure patients -- as many patients acquire access to the drug as possible over time. But they think there's a longer runway in terms of reaching out to patients and life cycle management opportunities would certainly attend to find us up to higher peak sales levels.

    Liisa Bayko -- JMP Securities -- Analyst

    Okay. Thank you very much for your comments. prize it.

    A. Brian Davis -- Chief financial Officer

    Thanks Liisa.

    Operator

    Thank you. And I'm showing no further questions at this time. I'd fancy to circle the convoke back to Mr. Matthew Pauls for any closing remarks.

    Matthew Pauls -- President and Chief Executive Officer

    Thank you. In summary, these fourth quarter and replete year 2018 results underscore that their strategy, their assets, their people, their capital and their infrastructure well position us for continued success in 2019 and beyond. Thank you for joining today's convoke and for your continued support.

    Operator

    Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may totality disconnect. Everyone acquire a mighty day.

    Duration: 33 minutes

    Call participants:

    Lindsay Rocco -- Investor Relations

    Matthew Pauls -- President and Chief Executive Officer

    Fredric Cohen -- Chief Medical Officer

    A. Brian Davis -- Chief financial Officer

    Esther Hong -- Janney -- Analyst

    Nick Rubino -- Stifel -- Analyst

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Liisa Bayko -- JMP Securities -- Analyst

    More SBBP analysis

    Transcript powered by AlphaStreet

    This article is a transcript of this conference convoke produced for The Motley Fool. While they strive for their foolish Best, there may live errors, omissions, or inaccuracies in this transcript. As with totality their articles, The Motley Fool does not assume any responsibility for your employ of this content, and they strongly cheer you to Do your own research, including listening to the convoke yourself and reading the company's SEC filings. delight observe their Terms and Conditions for additional details, including their Obligatory Capitalized Disclaimers of Liability.

    Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


    Nektar Therapeutics to Webcast Conference convoke for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium | killexams.com existent questions and Pass4sure dumps

    SAN FRANCISCO, Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that it will webcast an analyst and investor conference convoke with lead investigator of the REVEAL study, Dr. Adi Diab, and company management on Friday, March 1, 2019 at 3:00 p.m. Pacific Time during the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The event will result Friday's oral presentation by Dr. Diab of introductory data from the ongoing dose-escalation stage of the betray side 1/2 clinical study evaluating the combination of TLR agonist, NKTR-262, with a CD122-preferential IL-2 pathway agonist, bempegaldesleukin* (NKTR-214), in patients with locally advanced or metastatic solid tumors.

    Details on the Analyst Call:

    Date and Time: Friday, March 1, 2019 at 3:00 p.m. Pacific Time

    Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international)

    Passcode: 6970019

    The conference convoke will include lead investigator on the betray study, Dr. Adi Diab, aide Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. The webcast and slides for the conference convoke can live accessed through a link that is posted on the Investors section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. The event will furthermore live available for replay for two weeks on the company's website, www.nektar.com.

    Details on the Oral Presentation at ASCO-SITC:

    Abstract Title: "Phase Ib: introductory clinical activity and immune activation for NKTR-262 [TLR 7/8 

    agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid

    tumors (REVEAL side Ib/II Trial)"

    Abstract: #28

    Presenter: Dr. Adi Diab, MD Anderson Cancer Center

    Session: Oral Abstract Session B

    Date and Time: Friday, March 1, 2019, 1:00 p.m.-2:15 p.m. Pacific Time

    About NektarNektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Their R&D pipeline of modern investigational medicines includes treatments for cancer, auto-immune disease and habitual pain. They leverage Nektar's proprietary and proven chemistry platform in the discovery and design of their modern therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may live institute online at www.nektar.com.

    * rINN (recommended International Nonproprietary Name)

     

    View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-webcast-conference-call-for-analysts-and-investors-at-the-2019-asco-sitc-clinical-immuno-oncology-symposium-300801596.html


    American Outdoor Brands Corporation® Third Quarter Fiscal 2019 financial Release and Conference convoke Alert | killexams.com existent questions and Pass4sure dumps

    SPRINGFIELD, Mass., Feb. 22, 2019 /PRNewswire/ -- American Outdoor Brands Corporation (nasdaq global select:AOBC) today announced that it plans to release its third quarter fiscal 2019 financial results on Thursday, March 7, 2019, after the proximate of the market. The replete text of the press release will live available on the American Outdoor Brands web site at www.aob.com under the Investor Relations section.

    The company will host a conference convoke and webcast on March 7, 2019, to debate its third quarter fiscal 2019 financial and operational results. Speakers on the conference convoke will comprise James Debney, President and Chief Executive Officer, and Jeffrey D. Buchanan, Executive Vice President and Chief financial Officer. The conference convoke may comprise forward-looking statements. The conference convoke and webcast will open at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Those interested in listening to the conference convoke via telephone may convoke directly at (844) 309-6568 and reference conference identification number 9683518. No RSVP is necessary. The conference convoke audio webcast can furthermore live accessed live and for replay on the company's website at www.aob.com, under the Investor Relations section. The company will maintain an audio replay of this conference convoke on its website for a era of time after the call. No other audio replay will live available.

    About American Outdoor Brands Corporation American Outdoor Brands Corporation (nasdaq global select:AOBC) is a provider of character products for shooting, hunting, and rugged outdoor enthusiasts in the global consumer and professional markets. The Company reports two segments: Firearms and Outdoor Products & Accessories. Firearms manufactures handgun long gun, and suppressor products sold under the Smith & Wesson®, M&P®, Thompson/Center Arms™, and Gemtech® brands, as well as provides forging, machining, and precision plastic injection molding services. AOB Outdoor Products & Accessories is the industry leading provider of shooting, reloading, gunsmithing, gun cleaning supplies, specialty tools and cutlery, and electro-optics products and technology for firearms. They yield innovative, top character products under the brands Caldwell®; Wheeler®; Tipton®; Frankford Arsenal®; Lockdown®; BOG®; Hooyman®; Smith & Wesson® Accessories; M&P® Accessories; Thompson/Center Arms™ Accessories; Schrade®; faded Timer®; Uncle Henry®; Imperial®; BUBBA®; UST®;  Lasergrips®, Laserguard®, LiNQ®, Lightguard®, Defender Series™, Rail Master®, and LaserLyte.  For more information on American Outdoor Brands Corporation, convoke (844) 363-5386 or log on to www.aob.com.  

    Contacts:Liz Sharp, VP Investor RelationsAmerican Outdoor Brands Corporation(413) 747-6284lsharp@aob.com

    View original content to download multimedia:http://www.prnewswire.com/news-releases/american-outdoor-brands-corporation-third-quarter-fiscal-2019-financial-release-and-conference-call-alert-300800591.html

    SOURCE American Outdoor Brands Corporation

    Copyright (C) 2019 PR Newswire. totality rights reserved



    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [48 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [13 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [750 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1532 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [64 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [374 Certification Exam(s) ]
    Mile2 [3 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [39 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [279 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [12 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Dropmark : http://killexams.dropmark.com/367904/11788593
    Wordpress : http://wp.me/p7SJ6L-1FZ
    Dropmark-Text : http://killexams.dropmark.com/367904/12550696
    Blogspot : http://killexamsbraindump.blogspot.com/2017/12/free-pass4sure-920-106-question-bank.html
    RSS Feed : http://feeds.feedburner.com/EnsureYourSuccessWithThis920-106QuestionBank
    Box.net : https://app.box.com/s/v3e63p1mihwq6ygnznh96frr77zwlpp6






    Back to Main Page





    Killexams 920-106 exams | Killexams 920-106 cert | Pass4Sure 920-106 questions | Pass4sure 920-106 | pass-guaratee 920-106 | best 920-106 test preparation | best 920-106 training guides | 920-106 examcollection | killexams | killexams 920-106 review | killexams 920-106 legit | kill 920-106 example | kill 920-106 example journalism | kill exams 920-106 reviews | kill exam ripoff report | review 920-106 | review 920-106 quizlet | review 920-106 login | review 920-106 archives | review 920-106 sheet | legitimate 920-106 | legit 920-106 | legitimacy 920-106 | legitimation 920-106 | legit 920-106 check | legitimate 920-106 program | legitimize 920-106 | legitimate 920-106 business | legitimate 920-106 definition | legit 920-106 site | legit online banking | legit 920-106 website | legitimacy 920-106 definition | >pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | 920-106 material provider | pass4sure login | pass4sure 920-106 exams | pass4sure 920-106 reviews | pass4sure aws | pass4sure 920-106 security | pass4sure cisco | pass4sure coupon | pass4sure 920-106 dumps | pass4sure cissp | pass4sure 920-106 braindumps | pass4sure 920-106 test | pass4sure 920-106 torrent | pass4sure 920-106 download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |

    www.pass4surez.com | www.killcerts.com | www.search4exams.com | http://coqo.com/